NRx Defense Lands $11M DARPA Contract for Rapid Depression Treatment Trial — NRx Pharmaceuticals, Inc.

Event summary

NRx Defense Systems awarded $11.18M DARPA contract for SPARC-TMS trial evaluating robotic magnetic stimulation with NRX-101 for treatment-resistant depression.
Trial aims to validate single-day TMS treatment protocol, potentially changing standard of care for military and civilian depression treatment.
SPARC-TMS builds on prior DARPA-funded study showing 91% treatment response with traditional TMS + D-cycloserine (NRX-101 component).
Trial could serve as FDA registration study for NRX-101 in conjunction with TMS for treatment-resistant depression.
Study will be conducted at Harvard Medical School’s McLean Hospital, Arizona State University, and HOPE Therapeutics, with military hospital participation.

The big picture

This $11.18M DARPA contract represents a strategic pivot for NRx Defense into military mental health solutions, addressing a critical unmet need in treatment-resistant depression. The single-day treatment protocol, if validated, could disrupt current multi-week therapies and position NRX-101 as a potential breakthrough treatment. The trial's success would significantly expand NRx's addressable market beyond suicidal bipolar depression to the broader treatment-resistant depression population.

What we're watching

Trial Outcomes: Whether SPARC-TMS can replicate prior 91% response rate with single-day treatment protocol, potentially transforming depression treatment.
Regulatory Pathway: The pace at which FDA registration study status could be achieved for NRX-101 if trial results are positive.
Military Adoption: How quickly leading military hospitals expand participation and whether this leads to broader defense department contracts.